Another Alzheimer’s drug, made by Eli Lilly, shows promise to slow disease

Eli Lilly’s Alzheimer’s drug has shown promise to slow down cognitive and functional decline in people who are in early stages of the disease’s progression, according to results of phase 3 trial. This comes on the heels of Eisai and Biogen’s lecanemab, known by the brand name Leqembi, becoming the first to get US Food and Drug Administration’s (FDA) full approval, earlier this month, to slow down disease progression in adult patients with Alzheimer’s disease.